A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Regorafenib
Related studies linked through entity extraction aliases.
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
- Status
- WITHDRAWN
- Phase
- PHASE2
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
- Status
- RECRUITING
- Phase
- NA
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
- Status
- RECRUITING
- Phase
- N/A
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
- Status
- RECRUITING
- Phase
- PHASE3
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- N/A
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- N/A
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2